138.86 -0.34 (-0.24%)
After hours: 6:07PM EDT
|Bid||138.86 x 800|
|Ask||139.15 x 800|
|Day's Range||138.86 - 140.14|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.69|
|PE Ratio (TTM)||25.80|
|Forward Dividend & Yield||3.60 (2.58%)|
|1y Target Est||N/A|
The global demand for healthcare products and services will keep growing significantly. Here's your complete guide to finding the best healthcare stocks and ETFs.
Nothing frustrates investors more than companies failing to deliver for shareholders but managing to pay the CEO of those companies a King's ransom.On April 18, I covered 7 Companies That Are Closing the CEO-Worker Wage Gap in America. These are the kind of companies I like to write about. The ones that aren't sacrificing the financial happiness of the rank-and-file employees to keep the chief executives in a lavish lifestyle. The reality is that companies who pay their CEO significantly more than the salaries of the workers tend to experience poor shareholder returns. A recent study reported by Bloomberg and quoted in my previous article showed that the 100 S&P 500 companies with the lowest CEO pay outperformed the 100 with the highest by more than double between 2008 and 2018. InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo, whether you want to focus on the seven companies who've paid their CEOs outrageous sums in relation to the average employee or just the seven that have spent too much, the names in this article have unacceptable CEO-Worker wage gaps. * 10 Stocks to Sell Before They Give Back 2019 Gains Ultimately, this skewing of compensation will result in their stock's demise. American International Group (AIG)Source: Eflon via Flickr (Modified)Pay Ratio: 697:1Earning almost 700 times American International Group's (NYSE:AIG) median pay of $64,186, CEO Brian Duperreault is doing alright for himself. The company will argue that the CEO's 2017 pay was only that high because it had to pay $12 million to Duperreault to make up for the unvested equity awards he left behind when joining the insurance company in May 2017. Assuming the median pay at AIG didn't move much in 2018, Duperreault made a more pedestrian $16 million this past year or 249 times the average employee. How's AIG stock done since Duperreault was hired in 2017?AIG stock is down 21.5% in the 23 months since. If AIG doesn't get going soon, 249 times the median pay is going to appear more outrageous than it already is. CBS (CBS)Source: Shutterstock Pay Ratio: 595:1Once upon a time, former CBS (NYSE:CBS) CEO Les Moonves was considered a bit of a CEO celebrity, having turned the network into a TV powerhouse. And then the sexual harassment claims came out that painted the picture of a lecherous man using his power to hit on women. CBS investigators interviewed as many as 300 people about Moonves last December as part of its investigation into Moonves' actions and whether they breached the CEO's employment contract. The company found that they did, terminating him with cause and withholding Moonves' $120 million severance package. However, don't feel bad for the man. Between 2016-2018, Moonves made $186 million in total compensation over those three years, an average of $62 million -- 531 times the company's very high median pay of $116,654. CBS employees aren't exactly starving and yet they still made considerably less than Moonves over those three years. In that same period, CBS stock went sideways, delivering annual total returns of 36%, -6%, and -25% in 2016, 2017, and 2018 respectively. * 15 Stocks Sitting on Huge Piles of Cash If you were a CBS shareholder over the past three years, you got royally hosed, as did the employees. Discovery Communications (DISCA)Source: www.glynlowe.com via FlickrPay Ratio: 522:1I remember when Discovery Communications (NASDAQ:DISCA) launched the Oprah Winfrey Network (OWN) in January 2011. The 50/50 joint venture between the television broadcaster and one of America's wealthiest women was thought to be a slam dunk despite the more than $500 million DISCA invested in the cable network in the first two years of its existence. CEO David Zaslav, who's been the CEO for more than 12 years, was thought to be a brilliant judge of talent. However, OWN never really hit the big time when it comes to cable networks, and in December 2017, Winfrey sold half of her stake for $70 million, leaving Discovery with 75% control. However, that puts the value of OWN at approximately $280 million, much less than the amount invested by Discovery to get it up and running. And for that, Discovery shareholders paid Zaslav $208.9 million between 2016-2018, including a staggering $129.4 million in 2018, much of it ($102 million) in stock awards this past year. Also, Zaslav had $21 million of Discovery stock vest in 2018 in addition to the $129.4 million in total compensation. Over the past three years through April 18, DISCA shareholders have received an annualized total return of 1.8%, well behind the S&P 500 and other peers in the media business. TripAdvisor (TRIP)Source: JD Lasica/Cruiseable.com via FlickrPay Ratio: 481:1Any day now, TripAdvisor (NASDAQ:TRIP) is going to release its 2018 proxy showing CEO Stephen Kaufer's total compensation for the past year. In 2017, Kaufer was paid a total of $47.9 million in total with 98% in stock and option awards. If you exclude the stock and option awards, Kaufer only made a little over $1 million in 2017, around the same amount as the two previous years. So, if you're wondering why TRIP made the list, consider that Kaufer co-founded the company in February 2000. He would have a made a significant amount of money when TripAdvisor was sold to Expedia (NASDAQ:EXPE) in 2004 and then some more when it was spun-off in December 2011. Over the past three years, TRIP stock's delivered an annualized total return of -7.5% through April 18. And for that, Kaufer got almost $50 million in stock options and awards in 2017. * 10 High-Yielding Dividend Stocks That Won't Wilt It hardly seems worth it. That's especially true if you're one of the hardworking TripAdvisor employees earning just under $100,000 a year. Johnson & Johnson (JNJ)Source: Shutterstock Pay Ratio: 452:1It seems odd that I would pick on Johnson & Johnson (NYSE:JNJ), a stock that's delivered an annualized total return of 10% over the past three years through April 18, but that's what I'm going to do. In the past three years, CEO Alex Gorsky brought home cumulative total compensation of $76.8 million; not exactly Les Moonves territory, but much more substantial than the company's median pay of $66,000.In February of this year, I wondered if Gorsky was earning his pay. I argued that because JNJ shareholders had done well since he became CEO in December 2012, they probably wouldn't care. However, like America itself, if you don't speak up about what's wrong, you'll have to settle for whatever you get. Oh, and don't forget that Gorsky also made $43 million in 2018 through the CEOs stock options and awards that vested during the year. That's on top of his $20.1 million in total compensation. If you add that in, the pay ratio jumps to almost 1,000:1. Do you still think Gorsky's worth it? AT&T (T)Source: Shutterstock Pay Ratio: 366:1I've never been a fan of the AT&T (NYSE:T) purchase of Warner Media. To me, it was adding too much debt to a company that already had a significant amount. Some would call this type of acquisition by CEO Randall Stephenson a vanity project. I wouldn't disagree. Since AT&T closed the Warner Media merger in June 2018, T stock's appreciated by 5.8% including dividends. Considering its dividend is currently yielding 5.9%, most if not all its gains are from dividends. In the last three years (2016-2018), Randall Stephenson earned $86.2 million in total compensation and another $40.6 million in stock awards for an annual average of $42.3 million for a media ratio of 539:1, 47% higher than the ratio listed above. * 7 Red-Hot E-Commerce Stocks to Consider Until Stephenson gets the debt down, you can assume that the CEO will continue to deliver underwhelming returns for shareholders. Regeneron Pharmaceuticals (REGN)Source: Shutterstock Pay Ratio: 215:1The Regeneron Pharmaceuticals (NASDAQ:REGN) pay ratio is the least offensive of the seven companies on this list. I picked Regeneron primarily because it had one of the S&P 500's highest median annual pay at $123,418. It's one thing to have a pay ratio over 200 when your employees make $40,000 a year, but when they make three times that, to crank up the CEO-Worker wage gap by more than 200 times median pay is quite the accomplishment. So, how did CEO and founder Dr. Leonard Schleifer do it? Salary, a little bit of non-equity compensation, a $2.9 million cash bonus, and a whole lot of option awards. Over the past three years, Schleifer's been awarded $89.9 million in options. Also, in 2017 alone, Schleifer realized $90.8 million on the exercise of 250,000 shares. That right there doubles his compensation over the past three years, and I haven't even taken into account 2016 or 2015. If you add those in, the Regeneron pay ratio also balloons into the stratosphere.With almost six million shares of Regeneron stock, you would think the board and founder could come to some agreement as Warren Buffett has at his company that doesn't reek of greed. You know what they say, "If you own a successful business and want to relate to your staff, don't drive to work every day in a Bentley."I guess option awards is the good doctor's version of a Bentley. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post 7 Companies With Unacceptable CEO-Worker Wage Gaps appeared first on InvestorPlace.
Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.
Microsoft (NASDAQ:MSFT) stock reports earnings Wednesday after the market close. The company usually beats estimates, so the actual numbers may have little effect on Microsoft stock. However, both the stock price and the valuation continue to approach elevated levels.Source: Shutterstock Moreover, other factors could cause a near-term pullback. Although MSFT stock looks solid for the long term, investors should probably not buy this equity going into earnings. Expect Higher Earnings and RevenuesFor its fiscal third quarter, analysts forecast consensus earnings of $1 per share. The company earned 95 cents per share in the same quarter last year. They also expect revenues of $29.84 billion. If this prediction proves correct, it will represent an 11.3% increase from year-ago levels, when the Redmond, Washington-based software giant brought in $26.82 billion.InvestorPlace - Stock Market News, Stock Advice & Trading TipsInvestors should also note that Microsoft beat earnings in each of the last four quarters. MSFT may have only beaten estimates by one penny per share in the previous report. Still, most traders will probably expect that streak to continue in the upcoming release. Microsoft Stock Remains Solid for the Long TermIn many respects, things have never looked better for Microsoft stock. MSFT trades near all-time highs. The tech giant once depended on its operating system. Today it has turned itself around and boosted its profits by becoming one of the premier cloud computing companies. Cloud profits explain why Wall Street forecasts average profit increases of 14.5% per year for the next five years. * 10 Stocks to Sell Before They Give Back 2019 Gains Today, only Amazon (NASDAQ:AMZN) surpasses Microsoft in cloud-based revenues. It has also become a contender with Amazon for JEDI, a $10 billion project that would accelerate the Pentagon's adoption of cloud platforms.The company also continues to maintain one of the most solid balance sheets in corporate America. Its cash hoard of $127.66 billion may lag that of Apple (NASDAQ:AAPL), but it remains the only company other than Johnson & Johnson (NYSE:JNJ) to hold a AAA credit rating. That alone means that long-term investors should probably stay in MSFT and collect the $1.84 per share in annual dividends. Consider Exercising Caution at These LevelsStill, as it approaches the $1 trillion market cap for the first time, many wonder whether prospective buyers should get in now. The price-to-earnings (P/E) ratio has remained elevated since soon after Satya Nadella took over as CEO in 2014. Its current 29 trailing P/E ratio compares well to the average multiple of 33.3 over the last five years.However, other ratios point to overvaluation in Microsoft stock. The stock has risen more than 30% from its December lows. Moreover, MSFT trades at more than eight times sales, and its price-to-book ratio now exceeds 10. MSFT faces other possible issues. As my colleague Will Ashworth points out, allegations of sexual harassment within the company could lead to traders questioning the equity's multiple. Moreover, the odds slightly favor Amazon on the JEDI contract.To be sure, any significant drop in Microsoft stock would likely create a buying opportunity. However, new buyers should probably wait for that time before opening a position. Final Thoughts on MSFT StockAlthough Microsoft stock remains a solid, long-term pick, near-term factors probably mean that new investors should wait to buy. Yes, analysts expect earnings and revenue to rise on a year-over-year basis. Also, if the recent history of MSFT stock serves as an indication, it will likely beat those earnings.However, the P/E ratio has become elevated. Moreover, issues related to "me too" remain a cause for concern. With the stock up more than 30% in the last four months alone, any bad news could lead to a short-term drop in the equity.None of this news will make Microsoft stock a sell except to very-short-term traders. However, after the recent move higher, new buyers should probably hold off on MSFT going into earnings.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post Approach Microsoft Stock Cautiously as it Goes Into Earnings appeared first on InvestorPlace.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes CarMax, Inc (NYSE: KMX ) in the auto dealerships space, but he will take a closer look at CarGurus Inc (NASDAQ: CARG ). Instead ...
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Imbruvica’s trendsIn the first quarter, Johnson & Johnson (JNJ) and AbbVie’s (ABBV) Imbruvica reported 40% YoY (year-over-year) growth in
It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.CarGurus Inc. CARG : "Well, I gotta tell you my viewers, including you Scott, are smarter than I am.
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performanceIn the first quarter, Johnson & Johnson’s (JNJ) Pharmaceutical segment reported 7.9% YoY (year-over-year) growth in worldwide
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC business performance in international markets In the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported a 3% YoY
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)OTC businessIn the first quarter, Johnson & Johnson’s (JNJ) OTC (over-the-counter) business reported revenue of $1.09 billion, reflecting YoY
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Financial performance In the first quarter, Johnson & Johnson’s (JNJ) Consumer segment reported 2.2% YoY (year-over-year) growth in worldwide
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?(Continued from Prior Part)Stock price movementsOn April 17, Johnson & Johnson (JNJ) closed at $138.52, 0.36% higher than its previous closing price, 16.78% higher than its
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Legacy immunology drugs In the first quarter, Johnson & Johnson (JNJ) reported Remicade sales worth $1.10 billion, a YoY (year-over-year) fall of 20.6% on
Is Johnson & Johnson an Attractive Buy following Its Q1 Results?Revenue performance Johnson & Johnson (JNJ) reported its earnings results for the first quarter of 2019 on April 16. In its first-quarter earnings press release, the company
There's a new Kraft Heinz CEO that will be leading the company in the near future.Here's what we know about the new CEO for Kraft Heinz (NASDAQ:KHC). * The new Kraft Heinz CEO is Miguel Patricio. * He will be taking over as the CEO of the company starting on July 1, 2019. * This will have him taking over the position from Bernardo Hees, who will remain with the company as its CEO until June, 30, 2019. * Patricio is joining the company as the new Kraft Heinz CEO after spending two decades with Anheuser-Busch InBev (NYSE:BUD). * During his time with Anheuser-Busch InBev, Patricio served in various roles as part of its Executive Leadership team. * These roles include him serving as the company's Global Chief Marketing Officer from 2012 to 2018. * Prior to his, he was serving as the President of Asia Pacific from 2008 to 2012 for Anheuser-Busch InBev. * Before serving in that role, he was the President of North America for Anheuser-Busch InBev from 2006 to 2008. * Before starting his career at Anheuser-Busch InBev, Patricio worked at several other consumer companies. * Among these companies are Philip Morris (NYSE:PM), Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ). * 7 Tech Stocks With Too Much Risk, Not Enough Upside You can follow this link to learn more about new Kraft Heinz CEO Miguel Patricio and the experience he is bringing to the company.InvestorPlace - Stock Market News, Stock Advice & Trading TipsKHC stock started the day off up 1% on Monday morning, but is now largely unmoved as of the afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Miguel Patricio: 10 Things to Know About the New Kraft Heinz CEO appeared first on InvestorPlace.
Vertical Companies is among the largest vertically integrated businesses within the legal medical cannabis industry. The company is focused on "doing all things with the plant" except for operating a retail presence, said CEO Smoke Wallin.
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)Immunology revenue performance In the first quarter, Johnson & Johnson (JNJ) reported immunology sales of $3.25 billion, a YoY (year-over-year) rise of
Johnson & Johnson or Pfizer: Which Is the Best Pick in April?(Continued from Prior Part)EPS guidance In its first-quarter earnings press release, Johnson & Johnson (JNJ) raised the guidance for its adjusted diluted operational EPS from its
Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson's first-quarter profit down 14%, but the health care giant beat profit and revenue expectations, pushing up its ...
Major share benchmarks were mostly lower in Asia on Wednesday after China announced its economy grew at a 6.4% annual pace in the last quarter. Japan's Nikkei 225 index gained 0.3% to 22,289.32 and the ...
Silence is more “of the lambs” than golden at Aim-quoted Silence Therapeutics. Shares in the biotechnology company, which is backed by an array of high-profile institutional investors including Woodford and Invesco, have fallen from close to 250p to 58p in 18 months. Last August, Annalisa Jenkins quit after being chairwoman for 10 months.
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.